Tc-99m-HL91 is a hypoxia imaging biomarker. The aim of this study was to investigate the value of Tc-99m-HL91 imaging for hypoxia-induced cytosine deaminase (CD)/5-fluorocytosine (5-FC) gene therapy in a murine lung tumor model. C57BL/6 mice were implanted with Lewis lung carcinoma cells transduced with the hypoxia-inducible promoter-driven CD gene (LL2/CD) or luciferase gene (LL2/Luc) serving as the control. When tumor volumes reached 100 mm 3 , pretreatment images were acquired after injection of Tc-99m-HL91. The mice were divided into low and high hypoxic groups based on the tumor-to-non-tumor ratio of Tc-99m-HL91. They were injected daily with 5-FC (500 mg kg À1 ) or the vehicle for 1 week. When tumor volumes reached 1000 mm 3 , autoradiography and histological examinations were performed. Treatment with 5-FC delayed tumor growth and enhanced the survival of mice bearing high hypoxic LL2/CD tumors. The therapeutic effect of hypoxia-induced CD/5-FC gene therapy was more pronounced in high hypoxic tumors than in low hypoxic tumors. This study provides the first evidence that Tc-99m-HL91 can serve as an imaging biomarker for predicting the treatment responses of hypoxia-regulated CD/5-FC gene therapy in animal tumor models. Our results suggest that hypoxia imaging using Tc-99m-HL91 has the predictive value for the success of hypoxia-directed treatment regimens.
Introduction
Clinical and experimental data have demonstrated that tumor hypoxia is associated with aggressive disease and has a negative effect on radiotherapy and some forms of chemotherapy. [1] [2] [3] [4] Tumor hypoxia is primarily caused by deficiencies in tumor blood supply. It also constitutes a major difference between tumors and normal tissues. Therefore, it may represent a tumor-specific condition and can be exploited for selective gene therapy. The strategy is to selectively induce the expression of a therapeutic gene under hypoxic conditions and thereby preferentially kill hypoxic tumor cells. Hypoxia-responsive vectors regulate gene expression via hypoxia-responsive elements, which can be activated through the transcriptional complex hypoxia-inducible factor 1, [5] [6] [7] [8] [9] [10] such as cytosine deaminase (CD)/5-fluorocytosine (5-FC) cancer gene therapy.
Normal mammalian cells lack CD and are resistant to 5-FC. Various cancer cells, such as adenocarcinoma, fibrosarcoma, gliosarcoma and hepatocellular carcinoma, have been transduced with the CD gene, resulting in the expression of CD. [5] [6] [7] [8] [9] [10] These CD gene-modified cells have been compared with unmodified cells in terms of 5-FC sensitivity. The transfer of the CD gene followed by 5-FC treatment may be a promising regimen to eliminate cancer cells in an in vitro setting as well as in vivo. Utilization of the system of 5-FC and 5-fluorouracil (5-FU) is attractive in routine clinical treatment as antifungal and antitumor drugs. As they have already been well implemented in the clinical setting, extensive pharmacological information is already available for 5-FC and 5-FU.
The combination of CD/5-FC allows the nontoxic 5-FC to be converted to the toxic 5-FU by CD. 5-FU blocks the methylation reaction of dUMP to TMP by inhibiting thymidylate synthase. As a result, DNA synthesis and 5-fluor-UTP formation are disrupted and incorporated into RNA, thereby causing cell death in both dividing and non-dividing cells. Besides the antineoplastic effects of 5-FU, it also sensitizes tumor cells to irradiation. In addition, tumor-specific immunity is induced in this approach. [5] [6] [7] [8] [9] [10] Clinical tests to identify and quantify tumor hypoxia are still limited. Invasive techniques, such as oxygen electrode systems, [1] [2] [3] [4] are only limited to readily accessible tumor sites, such as cervix and head and neck tumors. Reliable techniques for the noninvasive, routine detection of tumor hypoxia are needed to allow selection of patients in need of more aggressive therapy. There is much interest in noninvasive methods, such as magnetic resonance spectroscopy and imaging of radiolabeled compounds.
Several radionuclide-labeled hypoxic markers, including F-18 fluoroazomycinarabinofuranoside, 11 F-18-misonidazole, 12, 13 Cu-60-ATSM 14 and I-125-azomycin galactopyranoside, 15 have been developed. Tc-99 m butyleneamine oxime (BnAO, Tc-99m-HL91) displays good hypoxia selectivity. Tc-99m-HL91 was shown to be increasingly retained in hypoxic tumors, which correlated with independent measures of tissue oxygen tension. 15 Significant correlations between antitumor responses and tumor uptakes of Tc-99m-HL91 were noted. 16, 17 A human study demonstrated the diagnostic value of Tc99m-HL91 in the squamous head and neck carcinoma. 18 In vitro studies have identified hypoxia-selective uptake of Tc-99m-HL91, with a significant increase in the uptake in the hypoxic state compared with the normoxic state. 17, 19, 20 Animal studies have also shown that Tc99m-HL91 is markedly increased in mice treated with hydralazine compared with controls. 19, 20 The aim of this study was to test our hypothesis that Tc-99m-HL91 imaging can be used to identify the efficacy of hypoxia-induced CD gene/5-FC gene therapy for cancer. Our results show that the tumor uptake of Tc-99m-HL91 can predict the antitumor response of the CD/5-FC cancer gene therapy.
Materials and methods

Radiolabeled tracer
Tc-99m-HL91 was prepared by reconstitution from a HL91 kit (Institute of Nuclear Energy Research, LungTan, Taiwan) with 4.5 ml, 900 MBq (24.3 mCi) of Tc-99 m sodium pertechnetate solution following the manufacturer's instructions. Each HL91 kit contained 200 mg of HL91 ligand, 20 mg of stannous chloride dihydrate, 40 mg of methylene diphosphonic acid and buffer salts in a 10-ml glass vial sealed under nitrogen atmosphere. Radiochemical purity determined by thin layer chromatography was typically 498%.
Cell lines
Murine Lewis lung carcinoma cells (LL2) (American Type Culture Collection, Manassas, VA) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with gentamicin (50 mg ml À1 ), 2 mM L-glutamine and 10% heat-inactivated fetal bovine serum at 37 1C in 5% CO 2 . For production of recombinant retroviruses encoding CD or luciferase, 293 cells were transfected with pCLNCX-6 Â HRECD or pCLNCX-6 Â HRELuc retroviral expression plasmid together with pCLEco packaging vector (Imgenex, San Diego, CA), and the supernatants containing viral particles were harvested 48 h later as previously described.
7 LL2 cells were infected with recombinant retroviruses encoding CD or luciferase in the presence of polybrene (8 mg ml
À1
). Clonal derivatives were isolated by G418 (400 mg ml
) selection and expanded to independent clones, generating LL2-6 Â HRECD (LL2/CD) and LL2-6 Â HRELuc (LL2/ Luc) cells. 7 In vitro cytotoxicity LL2/CD and LL2/Luc cells were plated in 96-well plates in tetraplicate at 5000 cells per well and cultured overnight. The medium was then replaced with DMEM containing various concentrations (100-500 mg ml
) of 5-FC (Sigma, St Louis, MO). A continuous flow of warmed, humidified gas containing 20% O 2 , 5% CO 2 and 75% N 2 for normoxia or 1% O 2 , 5% CO 2 and 90% N 2 for hypoxia was passed over the cells. 19 The pO 2 was monitored by an oxygen analyzer that controlled an automated valve system (Pro-Ox, BioSpherix, Redfield, NY). After 48 h, the tetrazolium salt 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT, 0.5 mg ml À1 final concentration; Sigma) assay was performed to determine cell viability. Sensitivity of cells to 5-FU was assessed by determining 50% inhibitory concentration (IC 50 ) that represents the concentration at which 50% inhibition of cell viability within 48 h with the MTT assay.
Animal tumor model
The experimental protocol adhered to the Animal Protection Act of Taiwan and was approved by the Laboratory Animal Care and Use Committee of National Cheng Kung University. Male C57BL/6 mice at 8 weeks of age were housed in groups of 4 or 5 per cage in a limited access area, at a mean temperature of 23 1C and a humidity of 50-60%, and allowed food and water ad libitum. The animals were maintained in a specific pathogen-free animal care facility under isothermal conditions with regular photoperiods.
Mice were implanted subcutaneously into the right hind leg with 5 Â 10 4 cells of LL2/CD or LL2/Luc cells. They were monitored 3 times per week for health status and tumor development using Vernier calipers. Tumor volumes were calculated according to the formula: tumor volume ¼ (length of tumor) Â (width of tumor) 2 Â 0.45. 7 When tumors grew to approximately 100 mm 3 , Tc-99m-HL91 imaging was performed. The ratio of the Tc-99m-HL91 uptake divided the tumors into low and high hypoxic groups. All the tumors in each group were further allocated evenly, randomly to two different treatment groups. One group received the intraperitoneal injection of 5-FC (500 mg kg
À1
, diluted in phosphate-buffered saline (PBS)) daily for 7 consecutive days (5-FC-treated tumor). The other group received PBS by intraperitoneal injection for 7 consecutive days (PBS-treated tumor). Survival times reflected the time at which mice were euthanized when their tumors exceeded 1000 mm 3 and subjected to autoradiography and histopathology for assessing the distribution of Tc-99m-HL91 within the tumor.
Antitumor responses were assessed by determining the values of tumor growth, absolute growth delay (aGD) and log cell kill. 11 Tumor growth was defined as the time in days for tumors to grow from 100 to 1000 mm 3 . The aGD was defined as the time in days for tumors to grow from 100 to 1000 mm 3 minus the average time in days for PBS-treated tumors to reach the same size. In addition, doubling time (Td) of PBS-treated tumors was calculated from the time in days required to double from 500 to 1000 mm 3 . The numbers of tumor cells killed by 5-FC treatment were assessed as log cell kill, from the formula: log cell kill ¼ 0.301 Â aGD/Td; where aGD is the median aGD for 5-FC-treated tumors and Td is the median Td for PBS-treated tumors.
Tc-99m-HL91 imaging in vivo Animals with tumor volumes reaching 100 mm 3 received injection of 74 MBq of Tc-99m-HL91 via the tail vein. After 2 h, the mice were injected intraperitoneally with chloral hydrate (370-400 mg kg
) for sedation to obtain the images using a gamma camera (Diacam; Siemens, Hoffman Estates, IL) equipped with a low-energy, highresolution collimator. Two experienced nuclear medicine physicians (B-F L and N-T C) assessed the images. The tumor-to-non-tumor (T/N) ratio of Tc-99m-HL91 was calculated by region of interest (ROI) manipulation. The ROI on the tumor was drawn manually. Another ROI on the contralateral thigh was used as the non-tumor reference. The background ROI was chosen to represent the tracer present within the blood pool and non-tumor tissue, excluding regions of increased uptake such as gastrointestinal tract. Maximum, minimum and average pixels within the ROI per slice were automatically stored as data files. T/N ratios were calculated by dividing the maximum value of pixels within a tumor ROI by the average value of pixels within the background ROI, using the formula of tumor ROI/non-tumor reference ROI. The range of T/N ratios was 1.86-3.46 for high hypoxic tumors and 1.26-1.85 for low hypoxic tumors.
ROI was computed by counting the number of pixels of the ROI divided by the number of pixels in the whole image. The purpose of the division was to normalize the feature, so that the feature values range from 0 to 1. Region roundness was computed by comparing the perimeter of the ROI with the circumference of a perfect circle with the same area. This perimeter comparison is justified by the fact that a perfect circle is a special shape that has the least perimeter-to-area ratio.
Autoradiography, histopathology and immunohistochemistry When tumor volumes exceeded 1000 mm 3 , mice were euthanized to remove the tumors 2 h after injection of 74 MBq of Tc-99m-HL91. The tumors were embedded in optimal cutting temperature compound (Sakura Finetek, Torrance, CA) and frozen in liquid nitrogen. The frozen tissue was sectioned on a cryostat (Bright Instruments, Huntingdon, UK). The sections were then applied to a BASMP2040 imaging plate inside the cassette (Fuji Photo Film, Tokyo, Japan) for 24 h. The imaging plate was assessed with a Fuji FLA5000 Multifunction Imaging System (Fuji). Autoradiograms were analyzed using Image Gauge, version 4.0 (Fuji). After autoradiography, the same section was stained with hematoxylin and eosin for histopathological examination to differentiate areas of viable cancer cells from necrosis.
For immunohistochemistry, the mice were perfusion fixed under deep anesthesia and post-fixed with 4% paraformaldehyde in PBS (pH 7.4), and the tumors were sectioned into 14-mm-thick slices by cryostat. The tumor slices were stained with anti-rat hypoxia-inducible factor-1a antibody (1:50; Santa Cruz Biotechnology, Santa Cruz, CA), followed by biotinylated goat antirabbit IgG (1:200; Santa Cruz Biotechnology). Finally, avidin-biotin HRP complex (Pierce, Rockford, IL) was added for 1 h, and 3, 3
0 -diaminobenzidine was used as the substrate chromogen. Results were recorded using a microscope (E400; Nikon Instech, Kawasaki, Japan).
Statistical analysis
Differences in tumor responses, including tumor growth, aGD and log cell kill between groups were compared with a two-way ANOVA. Kaplan-Meier survival curve and the log-rank test were used to evaluate survival time.
In vivo data presented are representative of duplicate experiments. P-values o0.05 were regarded statistically significant. Statistical tests were performed with SPSS software for Windows (version 18, SPSS, Chicago, IL).
Results
In vitro cytotoxicity
To assess whether the expression of CD could confer on LL2 cells increased sensitivity to 5-FC, LL2/CD and LL2/ Luc cells were treated with various doses of 5-FC under hypoxic or normoxic conditions for 48 h and their viability was measured with the MTT assay. As shown in Figure 1a , LL2/CD cells were susceptible to 5-FC in a dose-dependent manner under hypoxic conditions. In contrast, administration of 5-FC (0-500 mg ml 
Tc-99m-HL91 imaging in vivo
Of the 96 tumor-transplanted mice included in the study, 4 mice died before the beginning of therapy and 9 mice died before their tumor volumes reached 1000 mm 3 . Causes of death for these 9 mice appeared to be associated with complications of intraperitoneal injections (n ¼ 6) or general illness (n ¼ 3). Three mice were excluded because of no tumor formation. Therefore, after exclusion of 16 animals, a total of 80 tumors were evaluated for Tc-99m-HL91 imaging. Figure 1b shows the experimental timeline for the in vivo study. Treatment was initiated after Tc-99m-HL91 imaging when tumors grew to approximately 100 mm 3 . Tc-99m-HL91 imaging was performed 2 h after intravenous injection of 74MBq of Tc-99m-HL91. Among the 80 tumors, the T/N ratio of Tc-99m-HL91 calculated by ROI manipulation was variable, ranging from 1.26 to 3.46 (median value, 1.86). Scintigraphic images exhibited low amounts of Tc-99m-HL91 in a low hypoxic tumor (Figure 1c, left) and high uptake in a high hypoxic tumor (Figure 1d, left) . The imaging revealed little uptake in the lungs, heart, muscle and brain. Higher uptakes were seen in liver, gastrointestinal tract, kidneys and urinary bladder, indicating the major elimination pathways of the compound. Generally, the intense tracer uptake in the abdomen reflected hepatic and urinary elimination of the tracer.
Autoradiography, histopathology and immunohistochemistry When tumor volumes exceeded 1000 mm 3 , mice were euthanized and their tumors were sectioned on a cryostat (Figure 1b) . The slices were done for autoradiography and histological examination. The distribution of radioactivity at autoradiography was assessed by comparing the image densities, in which darker gray levels indicated higher radioactivity. The distribution of Tc-99m-HL91 radioactivity within tumors was not homogeneous. Autoradiography showed higher radioactivity in hypoxic than in normoxic tumors (Figures 1c and d, upper right) . In hematoxylin and eosin staining, the tumor tissue was divided into areas of viable cancer cells and necrosis by histopathological examination. The viable cancer cell layers bordering the necrotic area were defined as the hypoxic area. Cellular swelling, clumping of the nuclear chromatin, or both were characteristics of viable cancer cells in the hypoxic area. Regions of high Tc-99m-HL91 occurred in the periphery around the necrotic regions of the tumor (pink on the hematoxylin and eosin images; Figure 1d , middle right). The area where Tc-99m-HL91 activity was low corresponded to the histopathologically necrotic area. High uptake of Tc-99m-HL91 was seen mainly in the viable tumor cells (purple on hematoxylin and eosin images; Figure 1c , middle right). Compared with the low hypoxic group (Figure 1c, lower right) , the expression of hypoxia-inducible factor-1a increased in the high hypoxic group (Figure 1d, lower right) . These data clearly support the Tc-99m-HL91 imaging results, confirming the selectivity of Tc-99m-HL91 for high hypoxia in tumors.
Antitumor activity
Under low hypoxic conditions, tumor volume was significantly smaller in mice bearing LL2/CD tumors (n ¼ 10) than those bearing LL2/Luc tumors (n ¼ 10) under 5-FC treatment (P ¼ 0.0038. on day 14 and P ¼ 0.0147 on day 16; two-way ANOVA) (Figure 2a) . Furthermore, tumor volume was also significantly smaller in mice bearing LL2/CD tumors under 5-FC treatment (n ¼ 10) than those under PBS treatment (n ¼ 10) (P ¼ 0.0001 on day 14) (Figure 2a ). In the high hypoxic LL2/CD group, tumor volumes decreased on day 2 to day 6 under 5-FC treatment (n ¼ 10) compared with those under PBS treatment (n ¼ 10) (P ¼ 0.020 on day 4 and P ¼ 0.0040 on day 6; two-way ANOVA) ( Figure 2b ). As shown in Figures 2c and d ¼ 10) ; log-rank test). Thus, 5-FC treatment was more effective in high hypoxic LL2/CD tumors in enhancing the survival than in their low hypoxic counterparts. Hypoxia-regulated gene therapy specifically inhibited tumor growth under hypoxic conditions. Our results demonstrate that Tc-99m-HL91 uptake was an independent predictor of survival in tumor-bearing mice in response to hypoxia-regulated gene therapy. Mice tolerated well in all treatment regimens. As shown in Table 1 , the average weights of each group of mice slightly increased after the treatment. There were no differences in the body weight among the eight groups. These data suggest that 5-FC had no direct toxicity to mice. The Td of PBS-treated tumors were 1.72 ± 0.44 days for hypoxic and 2.10±0.57 for low hypoxic tumors (mean ± s.d.). As shown in Figure 3 , there were significant differences in the levels of tumor growth (Po0.0001), aGD (Po0.0001) and log cell kill (Po0.0001) between high (n ¼ 10) and low hypoxic (n ¼ 10) LL2/CD tumors under 5-FC treatment (two-way ANOVA). In contrast, the three values for tumor responses did not differ between high and low hypoxic LL2/Luc tumors under 5-FC treatment.
Discussion
Hypoxic cells within a tumor provide a powerful tumorspecific target for gene therapy. We have previously reported the use of a transcriptional targeting strategy that enables the genes of interest to be specifically expressed in cancer cells. 6, 7 Using luciferase as the Abbreviations: CD, cytosine deaminase; 5-FC, 5-fluorocytosine; PBS, phosphate-buffered saline. a C57BL/6 mice were implanted subcutaneously into the right hind leg with 5 Â 10 4 cells of LL2/CD or LL2/Luc cells. When their tumor volumes reached 100 mm 3 , pretreatment images were acquired after injection of Tc-99m-HL91. The mice were divided into low and high hypoxic groups based on the tumor-to-nontumor (T/N) ratio of Tc-99m-HL91. They were injected daily with 5-FC (500 mg kg À1 ) or PBS for 7 consecutive days. When tumor volumes reached 1000 mm 3 Log cell kill Figure 3 Analysis of levels of tumor growth, absolute growth delay (aGD) and log cell kill. C57BL/6 mice bearing 100 mm 3 LL2/CD or LL2/Luc tumors in low and high hypoxic groups were treated with 5-fluorocytosine (5-FC) (500 mg kg À1 ) or phosphate-buffered saline (PBS) for 7 consecutive days. Tumor responses were evaluated by the levels of tumor growth (a), aGD (b) and log cell kill (c). Tumor growth was defined as the time in days for tumors to grow from 100 mm 3 to 1000 mm 3 . The aGD was defined as the time in days for tumors to grow from 100 to 1000 mm 3 minus the average time in days for PBS-treated tumors to reach the same size. The numbers of tumor cells killed by 5-FC treatment were assessed as log cell kill, from the formula: log cell kill ¼ 0.301 Â aGD/Td; where aGD is the median aGD for 5-FC-treated tumors, and Td (doubling time defined as the time in days for tumors to grow from 500 to 1000 mm 3 ) is the median Td for PBS-treated tumors. Note that there were significant differences in the levels of tumor growth (Po0.0001), aGD (Po0.0001) and log cell kill (Po0.0001) between high (n ¼ 10) and low hypoxic (n ¼ 10) LL2/CD tumors under 5-FC treatment (two-way analysis of variance). High hypoxic tumors had good response to 5-FC treatment despite a rapid-growing pattern as solid tumors are more proliferative when they are more hypoxic. Data shown were the mean±s.d. (n ¼ 10 for each group), which were consistent in two independent experiments.
reporter gene, our previous study found the correlation between hypoxia-responsive element-regulated transgene expression and the extent of tumor hypoxia in mice, as determined by double immunofluorescence staining with anti-luciferase antibody (rhodamine) and anti-pimonidazole antibody (fluorescein).
7 LL2/Luc cells cocultured with LL2/CD cells under normoxic conditions did not show significant cytotoxicity following 5-FC treatment. By contrast, the luciferase activity of the cell lysate decreased under hypoxic conditions, indicating that cytotoxic effects after 5-FC treatment occurred. 7 Our previous study demonstrated that the uptake of Tc-99m-HL91 in LL2 cells was increased by approximately 10-16-fold under hypoxic conditions compared with normoxic conditions throughout the 4-h study. 19 Moreover, the use of Tc-99m-HL91 has been described for identifying tumor hypoxia in vitro and ex vivo. 17, [19] [20] [21] [22] [23] [24] The present study demonstrates for the first time, to our knowledge, that Tc99m-HL91 is useful as an imaging biomarker to predict the treatment responses of hypoxia-regulated CD/5-FC gene therapy in a mouse lung tumor model.
In the present study, the cytotoxic activity of hypoxiaregulated gene therapy in vitro was confirmed with the MTT assay. When the CD gene was induced by hypoxia, only LL2/CD cells were sensitive to 5-FC-mediated cell death in a dose-dependent manner (Figure 1a) , consistent with our previous finding. 7 After conversion from relatively non-toxic 5-FC, highly toxic 5-FU readily diffuses across cell membranes and induces cell death. [5] [6] [7] [8] [9] [10] Tc-99m-HL91 imaging allows noninvasive visualization and quantitation of the extent of the tumor hypoxia in a living mouse. In our result of autoradiography, high uptake of Tc-99m-HL91 corresponded to the histopathologically hypoxic area, consistent with previous reports. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Tc-99m-HL91 displays increased retention in hypoxic tumors and is correlated with independent measures of tissue oxygen tension. 15 An oxygen-specific retention mechanism may determine the amount of the radiotracer that is trapped in hypoxic tissues. Only viable cells that are hypoxic can retain hypoxia tracers, such as Tc-99m-HL91. Moreover, a 3.1-fold increase in tumor uptake of Tc-99m-HL91 is associated with the reduction of tumor blood flow. 24 The spatial distribution of hypoxia in animal tumors is not homogeneous. Tumors displaying a T/N ratio slightly above background had variable degrees of hypoxia. The T/N ratio reflects the amount of Tc-99m-HL91 retained within the tumor, and this depends on the number of viable cells that accumulate the radiotracer as well as the accumulation rate per cell. Therefore, a highly hypoxic cell fraction within a given tumor results in a high T/N ratio. As Tc-99m-HL91 is known to be a hypoxia-specific marker, we can assume that a high hypoxic cell fraction within a given tumor will result in a high T/N ratio. Although the classification into hypoxic and normoxic tumors based on the median pretreatment T/N ratio does not directly present the oxygenation status of the tumor tissue, the amount of Tc-99m-HL91 uptake is influenced by the number of viable cells that accumulate the tracer. Besides, our results also revealed that the therapeutic effect of hypoxia-induced CD/5-FC gene therapy was more pronounced in high hypoxic tumors than in low hypoxic tumors.
In LL2/CD tumors classified as high hypoxic tumors, 5-FC treatment markedly delayed tumor growth by about 7 days. In LL2/CD tumors classified as low hypoxic tumors, growth to the criterion volume was delayed by about 2 days under this treatment though it was not statistically significant (P ¼ 0.055). Compared with low hypoxic conditions, the degree of hypoxia-induced CD gene expression to convert the prodrug 5-FC to 5-FU was expected to be higher in high hypoxic conditions. As a result, reduction of LL2/CD tumor growth by 5-FC treatment was more prominent in high hypoxic tumors compared with low hypoxic tumors. Hypoxia, a hallmark of many solid tumors, is associated with angiogenesis and tumor progression. Tumor hypoxia detected by Tc99m-HL91 imaging suggests a poor prognosis. Our results, combined with recent studies using hypoxia imaging in cancer patients, provide evidence that hypoxia imaging using Tc-99m-HL91 is useful to characterize tumor hypoxia and to predict tumor outcome after radiation treatment. [16] [17] [18] Our findings indicate that Tc99m-HL91 imaging allows identifying tumor hypoxia and predicting success of hypoxia-induced CD gene therapy for cancer.
Our results demonstrate profound cancer cell death in vitro and tumor regression in vivo based on tumorspecific delivery of a prodrug-converter CD gene. An attractive feature of this gene therapy is that 5-FC has been utilized as an antifungal agent and 5-FU as an antitumor drug. Thus, extensive pharmacological information is available for both agents. In addition, the CD gene/5-FC system has a bystander effect, in which tumor cells not actually expressing the CD gene can be killed after exposure to 5-FC from their neighboring CDtransduced cells. In future, optimization of gene delivery, vector and prodrug dosages and administration modalities may further contribute to the translation of these promising experimental systems into clinical practice. It is worthwhile to investigate the correlation of Tc-99m-HL91 uptake with expression levels of CD in animal tumor models. Furthermore, Tc-99m HL 91 imaging provides a means for identifying patients who are most likely to benefit from the hypoxia-regulated cancer therapy. Therefore, the results with this tumor hypoxia marker warrant the testing of Tc-99m-HL91 in controlled human studies under the hypoxia-regulated cancer therapy.
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